BACKGROUND: This study assessed the efficacy and safety of treatment of chronic hepatitis C in children with pegylated interferon alpha and ribavirin. MATERIAL/ METHODS: Investigations were performed on 53 children with chronic hepatitis C, aged 8-17 years. Children were divided into 2 groups: naïve (n=29) and retreated (n=24). All children were administered a combined therapy with pegylated interferon (IFN) alpha-2b 1.5 mcg/kg/wk and ribavirin 15 mg/kg/d for 48 weeks. Mean baseline viral load was 0.456×10(6) IU/mL, mean alanine aminotransferase (ALT) activity was 45.8±24.3 IU/mL. No child had liver disease assessed greater than grade 2, stage 2 according to modified Scheuer scale. Serum hepatitis C virus (HCV) RNA in TW 12-EVR, TW 48-ETR, and W 72-sustained virologic response (SVR) with the polymerase chain reaction (PCR) method (Roche TaqMan) were evaluated. RESULTS: Sustained virologic response was achieved in 47% of children. The prevalence of relapses was 7.5%. The most important predictor of SVR in both groups was undetectable HCV RNA at TW 12. All retreated children who achieved partial EVR - (the HCV RNA level decreased more than 2 logs relative to baseline) were relapsers. In responders from both groups, baseline ALT activity was higher and baseline viral load was lower. In all children who achieved SVR, HCV RNA was undetectable 12 months later. CONCLUSIONS: Pegylated IFN and ribavirin are effective in treating chronic hepatitis C in children. Complete EVR is predictive of a sustained viral response. And high rate of relapses in retreated patients may suggest a longer duration of retherapy.
BACKGROUND: This study assessed the efficacy and safety of treatment of chronic hepatitis C in children with pegylated interferon alpha and ribavirin. MATERIAL/ METHODS: Investigations were performed on 53 children with chronic hepatitis C, aged 8-17 years. Children were divided into 2 groups: naïve (n=29) and retreated (n=24). All children were administered a combined therapy with pegylated interferon (IFN) alpha-2b 1.5 mcg/kg/wk and ribavirin 15 mg/kg/d for 48 weeks. Mean baseline viral load was 0.456×10(6) IU/mL, mean alanine aminotransferase (ALT) activity was 45.8±24.3 IU/mL. No child had liver disease assessed greater than grade 2, stage 2 according to modified Scheuer scale. Serum hepatitis C virus (HCV) RNA in TW 12-EVR, TW 48-ETR, and W 72-sustained virologic response (SVR) with the polymerase chain reaction (PCR) method (Roche TaqMan) were evaluated. RESULTS: Sustained virologic response was achieved in 47% of children. The prevalence of relapses was 7.5%. The most important predictor of SVR in both groups was undetectable HCV RNA at TW 12. All retreated children who achieved partial EVR - (the HCV RNA level decreased more than 2 logs relative to baseline) were relapsers. In responders from both groups, baseline ALT activity was higher and baseline viral load was lower. In all children who achieved SVR, HCV RNA was undetectable 12 months later. CONCLUSIONS: Pegylated IFN and ribavirin are effective in treating chronic hepatitis C in children. Complete EVR is predictive of a sustained viral response. And high rate of relapses in retreated patients may suggest a longer duration of retherapy.
Authors: Suzan El Naghi; Tawhida Y Abdel-Ghaffar; Hanaa El-Karaksy; Elham F Abdel-Aty; Mona S El-Raziky; Aleef A Allam; Heba Helmy; Hanaa A El-Araby; Behairy E Behairy; Mohamed A El-Guindi; Hatem El-Sebaie; Aisha Y Abdel-Ghaffar; Nermin A Ehsan; Ahmed M El-Hennawy; Mostafa M Sira Journal: World J Gastroenterol Date: 2014-04-28 Impact factor: 5.742
Authors: Natalia Dragomiretskaya; Anna Izha; Nikolay Kalinichenko; Mirosława Szark-Eckardt; Mariusz Klimczyk; Mirosława Cieślicka; Radosław Muszkieta; Krzysztof Prusik; Marek Napierała; Hanna Żukowska; Walery Zukow Journal: Open Med (Wars) Date: 2015-03-20
Authors: K Domagalski; M Pawłowska; A Tretyn; W Halota; M Pilarczyk; E Smukalska; K Linkowska; T Grzybowski Journal: Eur J Clin Microbiol Infect Dis Date: 2013-01-13 Impact factor: 3.267